

Identification of marker genes for predicting the osteogenic differentiation potential of mesenchymal stromal cells

Masami Kanawa ¹, Akira Igarashi ^{2,3}, Katsumi Fujimoto ^{3,4}, Tania Saskianti ^{3,5}, Ayumu Nakashima ⁶, Yukihito Higashi ⁷, Hidemi Kurihara ⁸, Yukio Kato ³ and Takeshi Kawamoto ^{3,9*}

¹ Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, 734-8533, Japan.

² Division of Advanced Technology and Development, BML, Inc., Saitama, 350-1101, Japan.

³ Department of Dental and Medical Biochemistry, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan; yyykka@hotmail.co.jp (Y.K)

⁴ Department of Molecular Biology and Biochemistry, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan.

⁵ Department of Pediatric Dentistry, Faculty of Dental Medicine, Universitas Airlangga, 60132, Indonesia.

⁶ Department of Stem Cell Biology and Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, 734-8533, Japan.

⁷ Research Center for Radiation Genome Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University; Hiroshima, 734-8533, Japan.

⁸ Departments of Periodontal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, 734-8533, Japan.

⁹ Writing Center, Hiroshima University, Higashi-Hiroshima 739-8512, Japan.

* Correspondence: tkawamo@hiroshima-u.ac.jp; Tel.: +81-82-424-6207

Abstract: Mesenchymal stromal cells (MSCs) have the potential to differentiate into a variety of mature cell types and are a promising source of regenerative medicine. The success of regenerative medicine using MSCs strongly depends on their differentiation potential. In this study, we sought to identify marker genes for predicting the osteogenic differentiation potential by comparing ilium MSC and fibroblast samples. We measured the mRNA levels of 95 candidate genes in nine ilium MSC and four fibroblast samples before osteogenic induction, and compared them with alkaline phosphatase (ALP) activity as a marker of osteogenic differentiation after induction. We identified 17 genes whose mRNA expression levels positively correlated with ALP activity. Next, we compared the mRNA levels of the 17 genes in ilium MSCs with those in jaw MSCs, which have different differentiation properties. The levels of seven out of the 17 genes were not substantially different between jaw and ilium MSCs, while the remaining 10 genes were expressed at significantly lower levels in jaw MSCs than in ilium MSCs. The mRNA levels of the seven similarly expressed genes were also compared with those in fibroblasts, which have little or no osteogenic differentiation potential. Among the seven genes, the mRNA levels of *IGF1* and *SRGN* in all MSCs examined were higher than those in any of the fibroblasts. These results suggest that measuring the mRNA levels of *IGF1* and *SRGN* before osteogenic induction will provide useful information for selecting competent MSCs for regenerative medicine.

Keywords: Mesenchymal stromal cell; osteogenesis; fibroblast; predictive marker gene; ALP activity;

1. Introduction

Mesenchymal stromal cells (MSCs) are multipotent precursor cells that differentiate into mature cells such as osteocytes, adipocytes, chondrocytes, neurocytes, and cardiomyocytes [1] [2] [3]. Previous studies have reported the use of MSCs in regenerative medicine and tissue engineering [4]; in particular, MSCs are applicable to clinical practice for a wide range of bone diseases, including osteoporosis, osteonecrosis, and fracture by trauma [5] [6]. [7] [8].

MSCs obtained from different tissues have differing differentiation abilities. For example, bone marrow-derived MSCs exhibit a higher osteogenic differentiation potential than adipose-derived MSCs [9]. In contrast, the adipogenic differentiation potential of adipose-derived MSCs is higher than that of bone marrow-derived MSCs, while MSCs derived from the synovium have a higher chondrogenic differentiation potential than bone marrow-derived MSCs [10]. Thus, MSCs obtained from different tissues seem to have intrinsic differentiation abilities related to their origin.

Herrmann et al. [11] reported that the chondrogenic differentiation potential of ilium MSCs was superior to that of tibia MSCs, although their osteogenic differentiation potentials were similar. In contrast, the chondrogenic and adipogenic differentiation potentials of jaw MSCs were lower than those of ilium MSCs, but the osteogenic differentiation potential of jaw MSCs was comparable to that of ilium MSCs [12] [13]. Therefore, as the specific differentiation ability of MSCs depends on their source, it is highly desirable to assess the differentiation potential of MSCs before their clinical application.

Recent studies have shown that surface antigens and specific genes expressed in undifferentiated MSCs before differentiation induction can serve as markers to predict their differentiation potential. For example, the CD271, CD146, and CD105 surface antigens have been reported as predictive markers of chondrogenic differentiation [14] [15] [16]. More recently, we identified predictive marker genes for chondrogenic and adipogenic differentiation of MSCs by taking advantage of the difference in differentiation abilities between ilium and jaw MSCs [17] [18]. However, we could not identify predictive markers for their osteogenic differentiation potential by using the difference between ilium and jaw MSCs because there was no difference. Although WNT16, the osteogenic differentiation predictive gene marker for tonsil-derived MSCs, was identified by Kim et al. [19], osteogenic differentiation predictive marker genes for bone marrow-derived MSCs have not yet been reported.

Fibroblasts are very similar to MSCs in terms of their origin and morphology [20]. Because there is little or no difference in the expression patterns of surface antigens between fibroblasts and MSCs, it is difficult to distinguish between these two cell types by assessing surface antigens [20]. However, Igarashi et al. [13] successfully identified MSC marker genes that can distinguish between fibroblasts and MSCs by using differences in gene expression profiles between these cells. Of the 95 candidate genes selected with DNA microarrays, nine were identified as MSC markers using the real-time quantitative polymerase chain reaction (RT-qPCR) for ilium, jaw, tibia, and femur MSCs, as well as fibroblasts. It has long been believed that fibroblasts have no differentiation potential [1]; however, Chen et al. [21] and Haniffa et al. [22] have recently reported that induced fibroblasts exhibit adipogenic, osteogenic, or chondrogenic differentiation phenotypes. Moreover, Fleury, et al. [23] found low, but significant, alkaline phosphatase (ALP) activity as an osteogenic differentiation marker after induction of fibroblasts. These findings suggest that osteogenic differentiation predictive markers can be identified by comparing osteogenic differentiation markers, such as ALP activity, with gene expression levels in fibroblasts and MSCs.

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. *Int. J. Mol. Sci.* **2021**, *22*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Lastname

Received: date
Accepted: date
Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

In this study, we sought to identify predictive markers of osteogenic differentiation for the selection of competent MSCs. Osteogenic differentiation was induced in nine ilium MSC samples and four fibroblast samples using osteogenic induction medium, and ALP activity was measured. We investigated the correlation between ALP activity in the 13 cell samples and the expression levels of 95 genes before induction. The results showed that there was a significant correlation between the expression levels of 17 genes and ALP activity. These genes can function as osteogenic predictive markers for the clinical application of MSCs.

2. Results

2.1 Selection of candidate genes for osteogenic predictive markers

To identify candidates for osteogenic differentiation predictive markers, we examined the correlation between gene expression levels before osteogenic induction of MSCs and the extent of MSC differentiation after induction. First, we measured the mRNA expression levels of 95 candidate genes in nine MSC and four fibroblast samples before induction (Table S1). After inducing osteogenic differentiation of these cells, we evaluated ALP activity on day 14 as an osteogenic differentiation marker. Correlation coefficients between the mRNA levels before induction and ALP activity after induction in the 13 cell samples were calculated. The results indicated that 17 out of 95 genes showed a significant positive correlation with ALP activity (Table 1). Thus, we identified 17 candidate predictive marker genes for the osteogenic potential of MSCs.

Table 1. Osteogenic predictive marker genes that are significantly positively correlated with ALP activity after osteogenic induction

| Gene | Full name | <i>r</i> |
|-----------------|--|----------|
| <i>MCAM</i> | melanoma cell adhesion molecule | 0.889** |
| <i>DNCI1</i> | dynein cytoplasmic 1 intermediate chain 1 | 0.824** |
| <i>HGF</i> | hepatocyte growth factor | 0.813** |
| <i>HLA-DRA</i> | major histocompatibility complex, class II, DR alpha | 0.780** |
| <i>HLA-DRB</i> | major histocompatibility complex, class II, DR beta | 0.762** |
| <i>SRGN</i> | serglycin | 0.727** |
| <i>SERPINI1</i> | serpin family E member 1 | 0.724** |
| <i>ACLY</i> | ATP citrate lyase | 0.705** |
| <i>P4HA2</i> | prolyl 4-hydroxylase subunit alpha 2 | 0.669* |
| <i>ITGA5</i> | integrin subunit alpha5 | 0.648* |
| <i>TFPI2</i> | tissue factor pathway inhibitor 2 | 0.620* |
| <i>KCTD12</i> | potassium channel tetramerization domain containing 12 | 0.617* |
| <i>LIF</i> | leukemia inhibitory factor | 0.614* |
| <i>PSMC5</i> | proteasome 26S Subunit, ATPase 5 | 0.589* |
| <i>CD74</i> | CD74 molecule | 0.585* |
| <i>TRIB2</i> | tribbles pseudokinase 2 | 0.579* |
| <i>IGF1</i> | insulin like growth factor 1 | 0.560* |

r : Pearson correlation coefficient; *P < 0.05, **P < 0.01

2.2 Comparison of expression levels of candidate genes for osteogenic predictive markers among three different cell sources

Previous studies have shown that the chondrogenic and adipogenic differentiation potentials of jaw MSCs are lower than those of ilium MSCs, but the osteogenic differentiation potential of jaw MSCs is comparable with that of ilium MSCs [12] [13]. Therefore, osteogenic differentiation predictive markers are expected to be expressed in jaw and ilium MSCs at similar levels. In addition, marker genes should be expressed at much lower levels in fibroblasts. We compared mRNA levels of the 17 candidate genes among the ilium and jaw MSCs, and fibroblasts (Figure 1). The mRNA expression levels of *HGF*, *IGF*, *KCTD12*, *TRIB2*, *SRGN*, and *TFPI2* in jaw MSCs were similar to those in ilium MSCs. The mRNA level of *SERPINI1* in jaw MSCs was higher than that in ilium MSCs. In contrast, the expression levels of *CD74*, *LIF*, *ITGA5*, *ACLY*, *DNC11*, *MCAM*, *HLA-DRA*, *HLA-DRB*, and *P4HA2* in jaw MSCs were much lower than those in ilium MSCs. Together, these results suggest that the seven genes, *HGF*, *IGF*, *KCTD12*, *TRIB2*, *SRGN*, *TFPI2*, and *SERPINI1*, can serve as osteogenic differentiation predictive markers. Importantly, the expression levels of these seven genes in both MSCs were much higher than those in fibroblasts, though the expression level of *PSMC5* was not different among ilium MSCs, jaw MSCs, and fibroblasts.




Figure 1. Comparison of osteogenic differentiation predictive markers among ilium mesenchymal stromal cells (MSCs) (n = 9), jaw MSCs (n = 5), and fibroblasts (FBs) (n = 4). mRNA levels of 11 marker genes were quantified before differentiation induction. The significance of differences between groups was analyzed by the Mann-Whitney U-test (* p < 0.05; ** p < 0.01; *** p < 0.001; n.s., not significant). Data are shown as means ± SEM.

138
139
140
141
142
143
144
145

2.3 Comparison of expression levels of osteogenic predictive markers in individual MSCs and fibroblasts

Effective osteogenic differentiation predictive markers should be able to distinguish between fibroblasts and MSCs. To compare the expression levels of the seven osteogenic differentiation predictive marker genes among individual fibroblasts and MSCs, we analyzed their expression profiles in four individual fibroblast and nine individual MSC samples using scatter plots (Fig. 2). The mRNA levels of *IGF1* and *SRGN* in all MSCs were higher than those in any of the examined fibroblasts. Namely, the minimum *IGF1* mRNA level in nine MSC samples was 221 times higher than the maximum value of those in the four fibroblast samples. Likewise, the minimum value of *SRGN* mRNA in the nine MSC samples was 12.5 times higher than the maximum value in the four fibroblast samples. Although the minimum value of *TRIB2* mRNA in the nine MSC samples was higher than the maximum value in the four fibroblast samples, the difference between them was marginal (1.1 times). Regarding *HGF*, *KCTD12*, *SERPIN11*, and *TFPI2*, the minimum mRNA values in the nine MSC samples were lower than the maximum values in the four fibroblast samples. Together, these results suggest that *IGF1* and *SRGN* are particularly potent osteogenic differentiation predictive markers.

146
147
148
149
150
151
152
153
154
155
156
158
159
160
161
162
163




Figure 2. Analysis of mRNA levels of osteogenic differentiation predictive markers in individual fibroblasts (FBs) and ilium mesenchymal stromal cells (MSCs). The horizontal bars represent the mean value for each group.

2.4. Comparison of differentiation predictive markers in three MSC lineages

Using a Venn diagram, we classified the 17 markers identified here together with eight chondrogenic and 11 adipogenic predictive markers reported in our previous studies. Among the 17 markers, *ACLY*, *CD74*, and *LIF* were identified as osteogenic, adipogenic, and chondrogenic predictive markers. In addition, *MCAM*, *DNC11*, *ITGA5*, and *P4HA2* were recognized as osteogenic and adipogenic predictive markers, but not as chondrogenic predictive markers. The remaining 10 genes, *HGF*, *SRGN*, *SERPINI1*, *TFPI2*, *KCTD12*, *TRIB2*, *IGF1*, *HLA-DRA*, *HLA-DRB*, and *PSMC5*, may serve only as osteogenic predictive markers. Thus, the 17 markers could be classified into three groups.




Figure 3. Classification of differentiation predictive marker genes for mesenchymal stromal cells into three lineages of osteogenic, adipogenic [18], and chondrogenic [17] differentiation.

3. Discussion

In this study, we screened for osteogenic differentiation predictive markers of MSCs. The expression levels of 95 candidate genes in ilium bone marrow-derived MSCs and fibroblasts were compared with ALP activity as the differentiation marker. Of the 95 genes, the expression profiles of 17 correlated significantly with ALP activity. By comparing the mRNA levels of the 17 genes in jaw and ilium MSCs, we excluded 10 genes that showed much lower expression in jaw MSCs than in ilium MSCs. Thus, we identified seven genes as predictive markers for osteogenic differentiation. Among these seven genes, the mRNA levels of *IGF1* and *SRGN* in all MSCs were higher than those in any

fibroblasts used in this study. Thus, these two genes may serve as effective markers for MSCs for use in bone regenerative therapy.

It is well-known that *IGF1* plays an important role in bone formation by osteoblasts [24]. Recently, Koch et al. [25] showed that transfection with an IGF1-expressing adenovirus induced osteogenic marker genes, including type I collagen, *Runx2*, and ALP genes, in MSCs. This suggests that MSCs expressing high levels of *IGF1* have a high osteogenic differentiation potential. Accordingly, our results demonstrate that mRNA levels of *IGF1* in undifferentiated MSCs can predict the degree of osteogenic differentiation after induction.

SRGN is a proteoglycan with a repeated structure of Ser-Gly dipeptides. [26]. Bae et al. [27] reported that the expression level of *SRGN* in MSCs was 33.8 times higher than that in fibroblasts. In this study, *SRGN* expression in ilium MSCs was 72.5 times higher than that in fibroblasts (Figure 1). In addition, Kristensen et al. [28] found that the protein levels of *SRGN* in the culture supernatant of MSCs increased at the beginning of osteogenic induction. These findings suggest that *SRGN* mRNA and protein are highly expressed in MSCs before osteogenic induction, and *SRGN* is involved in osteogenic differentiation.

For clinical applications of MSCs in regenerative medicine, it is important to use MSCs without fibroblast contamination. To distinguish between MSCs and fibroblasts, Igarashi et al. identified nine MSC marker genes. Six (*LIF*, *IGF1*, *SRGN*, *KCTD12*, *TRIB2*, and *DNC11*) out of these nine MSC marker genes were included in the 17 genes identified in the present study. These results suggest that these six genes can serve not only as MSC markers, but also as osteogenic differentiation predictive markers.

As shown in Figure 3, the 17 osteogenic differentiation predictive markers identified in this study could be divided into three groups with different potentials: one lineage with osteogenic differentiation potential, two lineages with osteogenic and adipogenic differentiation potential, and three lineages with osteogenic, adipogenic, and chondrogenic differentiation potential. For bone-regenerative therapy, MSCs are not required to have the ability to differentiate into all three lineages. Therefore, excellent markers for predicting the osteogenic differentiation potential can be powerful tools.

4. Materials and Methods

4.1 Cells and Cell Culture

Bone marrow-derived MSCs and fibroblasts were obtained from patients admitted to Hiroshima University Hospital as described previously [13] [17]. Fibroblasts were also obtained from Kurabo Industries [13]. The passage numbers of MSC and fibroblast cultures were 3-5 and 6-11, respectively. The detailed protocol for MSC culture was described previously by Igarashi et al. [13]. All processes were performed after approval by the Ethics Committee of Hiroshima University (D-88-4). Written informed consent was obtained from all patients.

4.2 Osteogenic Differentiation

MSCs and fibroblasts were induced for osteogenic differentiation according to previous studies [13] [29]. Briefly, 3×10^3 cells per cm^2 were seeded at in a 24-well plate and grown until confluence. Confluent cells were maintained in osteogenic induction medium for 14 days. ALP activity of the induced cells was measured [30], and the values were normalized using DNA content.

4.3 RT-qPCR

RT-qPCR analysis of 95 candidate genes was performed using the ABI Prism 7900 Sequence Detection System with TaqMan (Applied Biosystems) as described previously. [13] mRNA expression levels were normalized to the mRNA level of β -action. The TaqMan probe set IDs are listed Table S1.

4.4 Statistical analyses

All statistical analyses were performed using SPSS version 24. Pearson's correlation coefficient was calculated to analyze the correlation between gene expression levels and ALP activity. Gene expression levels among the three groups were evaluated using the Mann-Whitney U test.

5. Conclusions

In this study, we identified two osteogenic differentiation predictive markers, *SRGN* and *IGF1*. This makes it possible to evaluate the differentiation potential of MSCs in an undifferentiated state. These two markers will facilitate tissue engineering for bone diseases, including osteoporosis, osteonecrosis, and fracture due to trauma.

Supplementary Materials: Table S1: Correlation between gene expression levels before osteogenic induction and ALP activity after induction of four fibroblast and nine MSC samples.

Author Contributions: Conceptualization, M.K., Y.K., and T.K.; methodology, M.K., A.I., K.F., T.S., A.N., Y.H., and H.K.; formal analysis, M.K. and A.I.; investigation, M.K., A.I., and T.S.; resources, Y.H., and H.K. ; writing—original draft preparation, M.K. and T.K.; writing—review and editing, K.F., A.N., and Y.K.; visualization, M.F., A.I., and T.K. ; supervision, H.K., Y.K., and T.K. ; funding acquisition, M.K. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by JSPS KAKENHI (JP17K11541).

Informed Consent Statement: Written informed consent was obtained from all patients.

Data Availability Statement: The original data in this study are available on request.

Conflicts of Interest: The authors declare no potential conflicts of interest.s

References

- Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D. R., Multilineage potential of adult human mesenchymal stem cells. *Science* **1999**, *284*, (5411), 143-7.
- Bae, K. S.; Park, J. B.; Kim, H. S.; Kim, D. S.; Park, D. J.; Kang, S. J., Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. *Yonsei Med J* **2011**, *52*, (3), 401-12.
- Reger, R. L.; Tucker, A. H.; Wolfe, M. R., Differentiation and characterization of human MSCs. *Methods Mol Biol* **2008**, *449*, 93-107.
- Han, Y.; Li, X.; Zhang, Y.; Han, Y.; Chang, F.; Ding, J., Mesenchymal Stem Cells for Regenerative Medicine. *Cells* **2019**, *8*, (8).
- Kitoh, H.; Kawasumi, M.; Kaneko, H.; Ishiguro, N., Differential effects of culture-expanded bone marrow cells on the regeneration of bone between the femoral and the tibial lengthenings. *J Pediatr Orthop* **2009**, *29*, (6), 643-9.
- Zhao, D.; Cui, D.; Wang, B.; Tian, F.; Guo, L.; Yang, L.; Liu, B.; Yu, X., Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. *Bone* **2012**, *50*, (1), 325-30.
- Hu, L.; Yin, C.; Zhao, F.; Ali, A.; Ma, J.; Qian, A., Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. *Int J Mol Sci* **2018**, *19*, (2).
- Iaquinta, M. R.; Mazzoni, E.; Bononi, I.; Rotondo, J. C.; Mazziotta, C.; Montesi, M.; Sprio, S.; Tampieri, A.; Tognon, M.; Martini, F., Adult Stem Cells for Bone Regeneration and Repair. *Front Cell Dev Biol* **2019**, *7*, 268.

9. Xu, L.; Liu, Y.; Sun, Y.; Wang, B.; Xiong, Y.; Lin, W.; Wei, Q.; Wang, H.; He, W.; Wang, B.; Li, G., Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. *Stem Cell Res Ther* **2017**, *8*, (1), 275.
10. Bearden, R. N.; Huggins, S. S.; Cummings, K. J.; Smith, R.; Gregory, C. A.; Saunders, W. B., In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study. *Stem Cell Res Ther* **2017**, *8*, (1), 218.
11. Herrmann, M.; Hildebrand, M.; Menzel, U.; Fahy, N.; Alini, M.; Lang, S.; Benneker, L.; Verrier, S.; Stoddart, M. J.; Bara, J. J., Phenotypic Characterization of Bone Marrow Mononuclear Cells and Derived Stromal Cell Populations from Human Iliac Crest, Vertebral Body and Femoral Head. *Int J Mol Sci* **2019**, *20*, (14).
12. Matsubara, T.; Suardita, K.; Ishii, M.; Sugiyama, M.; Igarashi, A.; Oda, R.; Nishimura, M.; Saito, M.; Nakagawa, K.; Yamanaka, K.; Miyazaki, K.; Shimizu, M.; Bhawal, U. K.; Tsuji, K.; Nakamura, K.; Kato, Y., Alveolar bone marrow as a cell source for regenerative medicine: differences between alveolar and iliac bone marrow stromal cells. *J Bone Miner Res* **2005**, *20*, (3), 399-409.
13. Igarashi, A.; Segoshi, K.; Sakai, Y.; Pan, H.; Kanawa, M.; Higashi, Y.; Sugiyama, M.; Nakamura, K.; Kurihara, H.; Yamaguchi, S.; Tsuji, K.; Kawamoto, T.; Kato, Y., Selection of common markers for bone marrow stromal cells from various bones using real-time RT-PCR: effects of passage number and donor age. *Tissue Eng* **2007**, *13*, (10), 2405-17.
14. Watson, J. T.; Foo, T.; Wu, J.; Moed, B. R.; Thorpe, M.; Schon, L.; Zhang, Z., CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord blood. *Cells Tissues Organs* **2013**, *197*, (6), 496-504.
15. Hagmann, S.; Frank, S.; Gotterbarm, T.; Dreher, T.; Eckstein, V.; Moradi, B., Fluorescence activated enrichment of CD146+ cells during expansion of human bone-marrow derived mesenchymal stromal cells augments proliferation and GAG/DNA content in chondrogenic media. *BMC Musculoskelet Disord* **2014**, *15*, 322.
16. Fan, W.; Li, J.; Wang, Y.; Pan, J.; Li, S.; Zhu, L.; Guo, C.; Yan, Z., CD105 promotes chondrogenesis of synovium-derived mesenchymal stem cells through Smad2 signaling. *Biochem Biophys Res Commun* **2016**, *474*, (2), 338-344.
17. Kanawa, M.; Igarashi, A.; Fujimoto, K.; Higashi, Y.; Kurihara, H.; Sugiyama, M.; Saskianti, T.; Kato, Y.; Kawamoto, T., Genetic Markers Can Predict Chondrogenic Differentiation Potential in Bone Marrow-Derived Mesenchymal Stromal Cells. *Stem Cells International* **2018**.
18. Kanawa, M.; Igarashi, A.; Fujimoto, K.; Ronald, V. S.; Higashi, Y.; Kurihara, H.; Kato, Y.; Kawamoto, T., Potential Marker Genes for Predicting Adipogenic Differentiation of Mesenchymal Stromal Cells. *Applied Sciences-Basel* **2019**, *9*, (14).
19. Kim, Y. H.; Cho, K. A.; Lee, H. J.; Park, M.; Kim, H. S.; Park, J. W.; Woo, S. Y.; Ryu, K. H., Identification of WNT16 as a Predictable Biomarker for Accelerated Osteogenic Differentiation of Tonsil-Derived Mesenchymal Stem Cells In Vitro. *Stem Cells Int* **2019**, 2019, 8503148.
20. Soundararajan, M.; Kannan, S., Fibroblasts and mesenchymal stem cells: Two sides of the same coin? *J Cell Physiol* **2018**, *233*, (12), 9099-9109.
21. Chen, F. G.; Zhang, W. J.; Bi, D.; Liu, W.; Wei, X.; Chen, F. F.; Zhu, L.; Cui, L.; Cao, Y., Clonal analysis of nestin(-) vimentin(+) multipotent fibroblasts isolated from human dermis. *J Cell Sci* **2007**, *120*, (Pt 16), 2875-83.
22. Haniffa, M. A.; Wang, X. N.; Holtick, U.; Rae, M.; Isaacs, J. D.; Dickinson, A. M.; Hilkens, C. M.; Collin, M. P., Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. *J Immunol* **2007**, *179*, (3), 1595-604.
23. Cappellesso-Fleury, S.; Puissant-Lubrano, B.; Apoil, P. A.; Titeux, M.; Winterton, P.; Casteilla, L.; Bourin, P.; Blancher, A., Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. *J Clin Immunol* **2010**, *30*, (4), 607-19.

-
24. Youssef, A.; Aboalola, D.; Han, V. K., The Roles of Insulin-Like Growth Factors in Mesenchymal Stem Cell Niche. *Stem Cells Int* **2017**, 2017, 9453108. 325
326
25. Koch, H.; Jadowiec, J. A.; Campbell, P. G., Insulin-like growth factor-I induces early osteoblast gene expression in human mesenchymal stem cells. *Stem Cells Dev* **2005**, 14, (6), 621-31. 327
328
26. Toyama-Sorimachi, N.; Kitamura, F.; Habuchi, H.; Tobita, Y.; Kimata, K.; Miyasaka, M., Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. *J Biol Chem* **1997**, 272, (42), 26714-9. 329
330
27. Bae, S.; Ahn, J. H.; Park, C. W.; Son, H. K.; Kim, K. S.; Lim, N. K.; Jeon, C. J.; Kim, H., Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts. *Cell Tissue Res* **2009**, 335, (3), 565-73. 331
332
28. Kristensen, L. P.; Chen, L.; Nielsen, M. O.; Qanie, D. W.; Kratchmarova, I.; Kassem, M.; Andersen, J. S., Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells. *Mol Cell Proteomics* **2012**, 11, (10), 989-1007. 333
334
335
29. Kanawa, M.; Igarashi, A.; Ronald, V. S.; Higashi, Y.; Kurihara, H.; Sugiyama, M.; Saskianti, T.; Pan, H.; Kato, Y., Age-dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with fibroblast growth factor-2. *Cytotherapy* **2013**, 15, (9), 1062-72. 336
337
338
30. Bessey, O. A.; Lowry, O. H.; Brock, M. J., A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum. *J Biol Chem* **1946**, 164, 321-9. 339
340
341